An Arizona patient with synovial sarcoma has received a new immune cell therapy. Officials at HonorHealth Research Institute ...

Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...

Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...

Please provide your email address to receive an email when new articles are posted on . Half of the patients in the phase 1 trial had either a complete response or stable disease. The trial’s next ...

Please provide your email address to receive an email when new articles are posted on . Two first-in-class adoptive cell therapies show promise for patients with advanced melanoma or synovial sarcoma.

Afamitresgene-autoleucel is an autologous T-cell immunotherapy designed to target cancer cells in solid tumors expressing melanoma-associated antigen A4. The Food and Drug Administration (FDA) has ...

NORFOLK, Va. (WAVY) — Sarcoma, one of the rarest cancers in the world, makes up just 1% of all adult cancer diagnoses, but it is widely recognized as the ‘forgotten cancer,’ putting emphasis on just ...

While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma. It affects thousands across the UK ...